Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after...

Descripción completa

Detalles Bibliográficos
Autores principales: Matte, Paul, Ducreux, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368103/
https://www.ncbi.nlm.nih.gov/pubmed/37497421
http://dx.doi.org/10.1159/000530402
_version_ 1785077443396108288
author Matte, Paul
Ducreux, Michel
author_facet Matte, Paul
Ducreux, Michel
author_sort Matte, Paul
collection PubMed
description Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.
format Online
Article
Text
id pubmed-10368103
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-103681032023-07-26 Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind Matte, Paul Ducreux, Michel Case Rep Oncol Case Report Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine. S. Karger AG 2023-07-03 /pmc/articles/PMC10368103/ /pubmed/37497421 http://dx.doi.org/10.1159/000530402 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Matte, Paul
Ducreux, Michel
Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title_full Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title_fullStr Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title_full_unstemmed Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title_short Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
title_sort case report: vision loss induced by capecitabine in patient with preexisting left eyes blind
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368103/
https://www.ncbi.nlm.nih.gov/pubmed/37497421
http://dx.doi.org/10.1159/000530402
work_keys_str_mv AT mattepaul casereportvisionlossinducedbycapecitabineinpatientwithpreexistinglefteyesblind
AT ducreuxmichel casereportvisionlossinducedbycapecitabineinpatientwithpreexistinglefteyesblind

Ejemplares similares